Airshield® offers proven technology to protect against virus transmission at face-to-face interactions such as medical appointments, meetings and residential care home visits. Conceived, designed and manufactured in the UK, Airshield has undergone comprehensive testing by Nottingham Trent University which showed that Airshield removes 99% of virus particles.
Airshield's management team possesses a wealth of innovation, engineering, business management and healthcare experience.
Managing Director and Airshield's inventor Nigel Shepherd first started experimenting with ways to prevent the transmission of the virus in the air by capturing the aerosols through an air intake in 2020 and has been working on ever improving prototypes since. With a strong engineering background, Nigel has always applied validated engineering principles to achieve high quality and long-lasting value and this remains his ethos in the development and commercialisation of Airshield.
Director Jeremy Cummin has been involved in healthcare systems for some 40 years with several start-ups and disposals to his credit. He has consulted to major companies in the healthcare and pharmaceutical industries and has acted for several central government departments.
His experience is varied and includes a medical software business specialising in oncology and palliative care, an early-stage health informatics consultancy and an initiative bringing together digital health stakeholders to focus on collaborative volume business development.
Jeremy is a Member of the Royal Society of Medicine
Airshield Limited owns the patented technology (patent pending GB2012556.3) that makes Airshield unique. The product name Airshield® has been registered as a trademark in respect of classes 11 and 20 under UK00003594231 with effect from 11/02/21.